

RECEIVED
CENTRAL FAX CENTER

SEP 28 2004

1103326-0624

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Abrahamsson et al.
Serial No. : 09/581,967
Filed : June 19, 2000
For : ORAL FORMULATION FOR ILEUM ADMINISTERING
COMPRISING AN INHIBITOR COMPOUND OF THE ILEAL BILE
ACID TRANSPORT
Examiner : Micah Paul Young
Group Art Unit : 1615

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8	
I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on the date indicated below at the facsimile number 703-872-9306.	
Andrew Fessak	48,528
Agent Name	PTO Reg. No.
<i>Andrew Fessak</i>	<i>9/28/04</i>
Signature	Date of Signature

Date: September 28, 2004
Pages: 11 pages total
Facsimile: 1-703-872-9306

Mail Stop Amendment
Assistant Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(c)(2)**

Sir:

Applicants submit this communication and the attached Form PTO/SB/08A in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. A copy of the document listed on the Form PTO/SB/08A is enclosed as part of this communication.

Serial No. 09/581,967, filed June 19, 2000
Docket No. 1103326-0624
Page 2 of 2

TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed after three months of the filing date of this national application or the entry of the national stage as set forth in §1.491 in an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last but before the mailing date of either:

- (1) a final action under §1.113 or
- (2) a notice of allowance under §1.311,

whichever occurs first.

STATEMENT OR FEE

Accompanying this Information Disclosure Statement is:

A. ☐ a statement as specified in 37 C.F.R. §1.97(e).

OR

B. ☒ the fee set forth in 37 C.F.R. §1.17(p) for submission of an information disclosure statement under §1.97(c). (\$180.00).


METHOD OF PAYMENT OF FEE

- ☐ Attached is a check in the amount of \$ _____.
- ☒ Charge Account No. 23-1703 in the amount of \$ 180.00.

Authorization is given to the Assistant Commissioner to charge Deposit Account No. 23-703 for any additional fee which may be due in connection with this communication.

Dated: Sept. 28, 2004

Respectfully submitted,



Andrew Fessak
Reg. No. 48,528
Agent for Applicants

Customer No. 007470
White & Case LLP
Direct Dial: (212) 819-8437

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1419/PTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/581,967	
		Filing Date	June 19, 2000	
		First Named Inventor	Abrahamsson et al.	
		Art Unit	1615	
		Examiner Name	Micah Paul Young	
Sheet 1	1	1	Attorney Docket Number	1103326-0624

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		HIGAKI et al., "Inhibition of Ileal Na ⁺ /Bile Acid Cotransporter by S-8921 Reduces Serum Cholesterol and Prevents Atherosclerosis in Rabbits"; Arterioscler. Thromb. Vasc. Biol., Aug. 18(8), 1998; pages 1304-11.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP §901.04. *Draw Office that issued the document, by the two-letter code (WIPO Standard ST.16). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to the (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.